EKSO vs. ZIVO, ONCT, BNTC, EVAX, LSTA, CPIX, TXMD, FLGC, HLTH, and PYPD
Should you be buying Ekso Bionics stock or one of its competitors? The main competitors of Ekso Bionics include ZIVO Bioscience (ZIVO), Oncternal Therapeutics (ONCT), Benitec Biopharma (BNTC), Evaxion Biotech A/S (EVAX), Lisata Therapeutics (LSTA), Cumberland Pharmaceuticals (CPIX), TherapeuticsMD (TXMD), Flora Growth (FLGC), Cue Health (HLTH), and PolyPid (PYPD). These companies are all part of the "medical" sector.
Ekso Bionics (NASDAQ:EKSO) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.
In the previous week, Ekso Bionics had 5 more articles in the media than ZIVO Bioscience. MarketBeat recorded 5 mentions for Ekso Bionics and 0 mentions for ZIVO Bioscience. Ekso Bionics' average media sentiment score of 0.12 beat ZIVO Bioscience's score of 0.00 indicating that Ekso Bionics is being referred to more favorably in the media.
Ekso Bionics has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500. Comparatively, ZIVO Bioscience has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500.
Ekso Bionics received 219 more outperform votes than ZIVO Bioscience when rated by MarketBeat users. However, 61.11% of users gave ZIVO Bioscience an outperform vote while only 57.50% of users gave Ekso Bionics an outperform vote.
6.4% of Ekso Bionics shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 7.5% of Ekso Bionics shares are held by company insiders. Comparatively, 13.4% of ZIVO Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
ZIVO Bioscience has lower revenue, but higher earnings than Ekso Bionics. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Ekso Bionics, indicating that it is currently the more affordable of the two stocks.
ZIVO Bioscience has a net margin of 0.00% compared to Ekso Bionics' net margin of -79.48%. ZIVO Bioscience's return on equity of 0.00% beat Ekso Bionics' return on equity.
Ekso Bionics presently has a consensus target price of $10.00, indicating a potential upside of 624.64%. Given Ekso Bionics' higher probable upside, analysts clearly believe Ekso Bionics is more favorable than ZIVO Bioscience.
Summary
Ekso Bionics beats ZIVO Bioscience on 10 of the 17 factors compared between the two stocks.
Get Ekso Bionics News Delivered to You Automatically
Sign up to receive the latest news and ratings for EKSO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EKSO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ekso Bionics Competitors List
Related Companies and Tools
